Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/01/049008
CTRI/2023/01/049008
Recruiting
未知

Evaluation of endocrine and metabolic characteristics in different phenotypes of Polycystic ovarian syndrome (PCOS)

ESIPGIMSR Basaidarapur Delhi0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: E282- Polycystic ovarian syndrome

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: E282- Polycystic ovarian syndrome
Sponsor
ESIPGIMSR Basaidarapur Delhi
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
ESIPGIMSR Basaidarapur Delhi

Eligibility Criteria

Inclusion Criteria

  • •Ovulatory dysfunction
  • •Clinical hyperandrogenism
  • •Polycystic Ovaries

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
To study the causes of irregular menses in young girls.
CTRI/2020/09/027760AIIMS
Active, not recruiting
Not Applicable
Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism and Cardiovascular Risk - Pioglitazone in PCOSPolycystic Ovary Syndrome includes anovulatory hyperandrogenism, hyperinsulinemia and/or dyslipidemia. Adiponectin and interleukin-6 are adipocytokines that have been related to abdominal fat excess and/or impaired insulin sensitivity. These cytokines -together with other indices of low-grade inflammation-, sucj as C-reactive protein (CRP), and the neutrophil count, contribute to link insulin-resistant states with cardiovascular disease risks.
EUCTR2005-004163-39-ESHospital Sant Joan de Déu40
Recruiting
Not Applicable
Effect of metformin and simvastatin in treatment of polycystic ovarian syndromePolycystic ovarian syndrome.Polycystic ovarian syndromeE28.2
IRCT20140525017827N8Shiraz University of Medical Sciences144
Completed
Not Applicable
se of insulin sensitisers to revert metabolic syndrome
ISRCTN58810841Hospital Sant Joan de Deu (Spain)52
Not yet recruiting
Not Applicable
A study to assess the endogenous metabolic alterations and pharmacokinetic·pharmacodynamic characteristics after oral administrations of dapagliflozin in healthy and obese adult volunteersEndocrine, nutritional and metabolic diseases
KCT0007864Kyungpook National University Hospital30